ASLAN Pharmaceuticals initiates Phase 2b study of eblasakimab for atopic dermatitis
Newswires MT 2022
|
|
|
|
|
||||
|
||||
Technical Analysis Trends ASLAN PHARMACEUTICALS LIMITED
Short term | Middle term | Long term | |
Tendencies | Bearish | Bearish | Bearish |
Evolution of the income statement
To sell ![]() To buy |
|
Medium consensus | SURPASS |
Number of analysts | 4 |
Last closing price |
$0.92 |
Average target price |
$8.00 |
Average Spread / Target | 769% |
Comments are closed.